Cancer Therapy
Data on cancer therapy detailed by W. Scheuer and co-authors
Published in Cancer Law Weekly, February 13th, 2010
"Trastuzumab is a humanized monoclonal antibody targeting HER2 and has proven survival benefit for women with HER2-positive early and metastatic breast cancer. Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1. We investigated the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
Source: Cancer Law Weekly (2010-02-13)
More Articles from Cancer Law Weekly
- American Academy of Dermatology
American Academy of Dermatology Lauds U.S. Federal Trade Commission for Protecting the Public From False Health and Safety Claims About Indoor Tanning - Asbestos Disease Awareness Organization ADAO
Asbestos Disease Awareness Organization ADAO Announces New Staff and Program for 2010 - Biomoda, Inc.
Biomoda Supports Nebraska Legislation to Screen Veterans for Lung Cancer - Chase
Five California Charities Win Grants from Chase Through Facebook Program - Life Sciences
New findings from University of Surrey in the area of life sciences published - Pancreatic Cancer Action Network
President Obama's State of the Union Address: a Statement From the Pancreatic Cancer Action Network - More from this issue of Cancer Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
